|
Gene: NSUN2 |
Gene summary for NSUN2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NSUN2 | Gene ID | 54888 |
Gene name | NOP2/Sun RNA methyltransferase 2 | |
Gene Alias | MISU | |
Cytomap | 5p15.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q08J23 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54888 | NSUN2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.00e-07 | 5.36e-01 | -0.0811 |
54888 | NSUN2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.32e-05 | 4.29e-01 | -0.1088 |
54888 | NSUN2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.66e-14 | 5.13e-01 | -0.1954 |
54888 | NSUN2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.16e-04 | 3.37e-01 | -0.1464 |
54888 | NSUN2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 8.90e-05 | 4.11e-01 | -0.059 |
54888 | NSUN2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.10e-03 | 3.70e-01 | 0.0338 |
54888 | NSUN2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 9.21e-03 | 4.32e-01 | 0.0112 |
54888 | NSUN2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.01e-02 | 3.25e-01 | 0.0588 |
54888 | NSUN2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.69e-06 | 3.98e-01 | 0.294 |
54888 | NSUN2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 6.39e-04 | 7.74e-01 | 0.3487 |
54888 | NSUN2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.24e-06 | 4.58e-01 | 0.3859 |
54888 | NSUN2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 8.46e-04 | 5.84e-01 | 0.2585 |
54888 | NSUN2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.79e-34 | 1.10e+00 | 0.3005 |
54888 | NSUN2 | A015-C-203 | Human | Colorectum | FAP | 8.85e-05 | -8.18e-02 | -0.1294 |
54888 | NSUN2 | A002-C-203 | Human | Colorectum | FAP | 2.10e-02 | -1.32e-01 | 0.2786 |
54888 | NSUN2 | A015-C-104 | Human | Colorectum | FAP | 1.66e-05 | -1.39e-01 | -0.1899 |
54888 | NSUN2 | A002-C-016 | Human | Colorectum | FAP | 2.72e-07 | -2.19e-01 | 0.0521 |
54888 | NSUN2 | A002-C-116 | Human | Colorectum | FAP | 9.90e-09 | -1.53e-01 | -0.0452 |
54888 | NSUN2 | F034 | Human | Colorectum | FAP | 8.94e-05 | -1.39e-01 | -0.0665 |
54888 | NSUN2 | LZE2T | Human | Esophagus | ESCC | 7.31e-04 | 4.89e-01 | 0.082 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19023696 | Lung | IAC | negative regulation of RNA catabolic process | 18/2061 | 75/18723 | 1.06e-03 | 1.26e-02 | 18 |
GO:00064038 | Lung | IAC | RNA localization | 37/2061 | 201/18723 | 1.18e-03 | 1.37e-02 | 37 |
GO:00064053 | Lung | IAC | RNA export from nucleus | 19/2061 | 84/18723 | 1.66e-03 | 1.74e-02 | 19 |
GO:00346557 | Lung | IAC | nucleobase-containing compound catabolic process | 63/2061 | 407/18723 | 3.31e-03 | 2.84e-02 | 63 |
GO:00159317 | Lung | IAC | nucleobase-containing compound transport | 38/2061 | 222/18723 | 3.85e-03 | 3.20e-02 | 38 |
GO:00085444 | Lung | IAC | epidermis development | 51/2061 | 324/18723 | 5.51e-03 | 4.11e-02 | 51 |
GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
GO:000640318 | Oral cavity | OSCC | RNA localization | 150/7305 | 201/18723 | 6.90e-25 | 1.98e-22 | 150 |
GO:000691317 | Oral cavity | OSCC | nucleocytoplasmic transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
GO:005116917 | Oral cavity | OSCC | nuclear transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:003238615 | Oral cavity | OSCC | regulation of intracellular transport | 218/7305 | 337/18723 | 6.91e-22 | 1.41e-19 | 218 |
GO:000640118 | Oral cavity | OSCC | RNA catabolic process | 184/7305 | 278/18723 | 2.71e-20 | 4.19e-18 | 184 |
GO:00510287 | Oral cavity | OSCC | mRNA transport | 101/7305 | 130/18723 | 2.19e-19 | 3.15e-17 | 101 |
GO:005065714 | Oral cavity | OSCC | nucleic acid transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
GO:005065814 | Oral cavity | OSCC | RNA transport | 120/7305 | 163/18723 | 2.31e-19 | 3.18e-17 | 120 |
GO:005123614 | Oral cavity | OSCC | establishment of RNA localization | 121/7305 | 166/18723 | 6.38e-19 | 8.24e-17 | 121 |
GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
GO:005116817 | Oral cavity | OSCC | nuclear export | 112/7305 | 154/18723 | 1.70e-17 | 1.56e-15 | 112 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NSUN2 | SNV | Missense_Mutation | c.1876N>A | p.Asp626Asn | p.D626N | Q08J23 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
NSUN2 | SNV | Missense_Mutation | rs745927756 | c.658N>T | p.Arg220Cys | p.R220C | Q08J23 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NSUN2 | SNV | Missense_Mutation | novel | c.2117N>G | p.Val706Gly | p.V706G | Q08J23 | protein_coding | deleterious(0.01) | benign(0.141) | TCGA-AO-A1KP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
NSUN2 | SNV | Missense_Mutation | rs759251595 | c.2008N>T | p.Ala670Ser | p.A670S | Q08J23 | protein_coding | tolerated(0.76) | benign(0.02) | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
NSUN2 | insertion | Nonsense_Mutation | novel | c.1617_1618insTTTCATCTTATTTTTTTACTTACAGGTTATTAACACA | p.Asp540PhefsTer11 | p.D540Ffs*11 | Q08J23 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | ||
NSUN2 | deletion | Frame_Shift_Del | novel | c.403delN | p.Ile135SerfsTer2 | p.I135Sfs*2 | Q08J23 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
NSUN2 | SNV | Missense_Mutation | rs746142475 | c.2167G>A | p.Ala723Thr | p.A723T | Q08J23 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NSUN2 | SNV | Missense_Mutation | novel | c.259G>A | p.Ala87Thr | p.A87T | Q08J23 | protein_coding | deleterious(0.04) | possibly_damaging(0.616) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NSUN2 | SNV | Missense_Mutation | c.178N>A | p.Glu60Lys | p.E60K | Q08J23 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
NSUN2 | SNV | Missense_Mutation | novel | c.2001N>G | p.Asn667Lys | p.N667K | Q08J23 | protein_coding | tolerated(0.93) | benign(0) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |